SCAI slides: Resolute at 3 years in patients with diabetes

Kimberly A. Skelding, MD, of Geisinger Medical Center in Danville, Pa., presented three-year results of patients with diabetes mellitus who were enrolled in the Resolute U.S. trial at the Society of Cardiovascular Angiography and Interventions (SCAI) scientific sessions in Orlando, Fla.

The post-hoc analysis of patients treated with the Resolute drug-eluting stent for coronary artery disease found low rates of target lesion failure (10.8 percent in the diabetic subgroup) and target lesion revascularization (6.7 percent) and no stent thrombosis at three years. The researchers defined target lesion failure as cardiac death, target vessel MI and target lesion revascularization.


Skelding is director of Cardiovascular Genomics and Cardiovascular Research at the Geisinger Center for Health Research.